Eddingpharm Pays $2.7 Million Upfront for China Rights to Bone Drug
publication date: Oct 18, 2013
Eddingpharm has in-licensed greater-China rights to a novel osteoporosis treatment from Ablynx, a Belgium biopharma. The drug candidate, ALX-0141, is an anti-RANKL nanobody that has successfully completed a Phase I double-blind trial. Eddingpharma paid $2.7 million upfront, plus it will make additional milestone payments and pay royalties up to 20%, based on sales. Eddingpharm will also underwrite clinical development of the molecule in greater China. More details....
Stock Symbol: (BR: ABLX)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.